ISRG is currently developing the following drugs: Administration Of Is-002, Firefly Fluorescent Imaging, Robotic-Assisted Laparoscopic Prostatectomy With Pelvic Lymph Node Dissection, Is-001, Is-001. These drug candidates are in various stages of clinical development as the company works toward FDA approval.